Exchange: NYSE·Updated 07:53 PM EST
ANVS logo

ANVS Annovis Bio Inc

$0.7113
$0.0371
(4.96%)
Today
Closed $0.7113
$0.0187
(2.63%)
After Hours
Reported EarningsNov 13
Mkt Cap$44.12M
Vol1.44M

About ANVS

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
74

Bullish Sentiment

How do you feel about ANVS?

StMichaelTwits
$ANVS Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), is scheduled to speak today, from 11:25 a.m. to 11:55 a.m. ET (8:25 a.m. to 8:55 a.m. PT). Presentation Details • Event. Pharma Partnering Summit 2026 in Boston, MA. • Session Title. "Restoring Proteostasis in Alzheimer's and Parkinson's Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins". • Focus. She will review Annovis Bio's clinical progress, upcoming milestones, and lead drug candidate buntanetap, alongside one-on-one meetings with biotech and pharmaceutical industry representatives. Note: Annovis Bio also has a separate oral presentation scheduled today at 3:52 p.m. ET at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston covering the clinical trial design and baseline characteristics of buntanetap's pivotal early Alzheimer's study.
20
Rayvio_News_Filter
$ANVS 🏥 Annovis Bio, Inc. announced that an independent Data and Safety Monitoring Board issued a second consecutive positive recommendation for its Phase 3 DUET-AD trial in early Alzheimer’s disease, recommending continuation without modification after a 12-month safety review. Curated for market relevance
21
Action80gr
$ANVS Excellent news for Annovis Bio! A second consecutive positive DSMB recommendation represents an important vote of confidence in Buntanetap’s safety profile and the progress of the DUET-AD clinical trial. Now we look ahead with optimism. The upcoming results expected in March 2027 could represent a major milestone for the company and all shareholders who continue to believe in this project. We hope the market will finally begin to recognize the value of Annovis’ research, its clinical progress, and its long-term potential, translating these achievements into a meaningful revaluation of the stock. Let’s stay united, confident, and patient. True investment conviction means believing in the journey before the market recognizes its full potential. The best may still be ahead. Go Annovis! 🚀💪📈
1
17
Marypennsylvanialand
$ANVS you can say a lot of things about Maria, but to me, she's overtly homest and overly transparent. The fact that they are preparing for a NDA, tells me they are supremely confident in the readouts in March.
17
Dopamineaddict
$ANVS Again, despite some of my Monday morning quarterbacking, I would like to thank the Annovis team for their Herculean effort in pursuing a treatment for Alzheimer’s and Parkinson’s.
21
stiilthz
$ANVS Annovis Bio is scheduled to participate in the Pharma Partnering Summit 2026 on November 19–20, 2026, at the Hilton Hotel Logan Airport in Boston, Massachusetts. Speaker: Maria Maccecchini, Ph.D., Founder, President, and CEO. Focus: Presenting clinical progress on lead candidate buntanetap (an oral Phase 3 therapy for Alzheimer's and Parkinson's diseases) and holding 1-on-1 meetings with pharma and biotech representatives. Summit Themes: Business development and licensing, R&D collaborations, investment, M&A, and deal-making. Lock in Maria!
17
ILikeDaStocks
$ANVS IMO, it's important for those of us who are true believers in the ability of buntanetap to see the current stock price as opportunity granted by the shorts. If this simple to administer drug with virtually no side effects is truly effective in treating AD, at least a $10B MC will follow which places the stock price in the range of $140, or 18,000%+ from today's price. And if the 18-month final readout from the P3 trail is as dramatic as it may be, the value of buntanetap (and our shares) will be enormous! So, maybe the shorts aren't all bad! 😂
17
jackgeoffreys
$ANVS similar to others I got in at $25 in early 2021, sold a little bit when it was above $100 (obviously not nearly enough) and have been accumulating ever since, mostly over the last week. Hard to believe my initial position was 400 shares and after today it’ll be more than 10 times that amount. Ironically if this goes back to ~$25+ that would be amazing but I’m mentally and financially prepared for it to go to zero. While management could have handled the raises better, I have used this as an opportunity to accumulate. Hopefully I can look back at this post in about 2 years and say I made the right decision. GLTA longs! It’s been a wild ride… mostly on the way down but I’m cautiously optimistic we’ll see some strong upswings in the coming months. Cheers from Toronto! 🍁💵
18
Fritzipooch
$ANVS Took advantage of sub $1.00 prices today and bought several thousand more. In it to win it. “No guts, no glory” as General Patton was famous for saying!
18
stiilthz
$ANVS i mean with these prices we talking about 75-125x return potential for ur investment, maybe even more. So knowing that, ive decided that ill invest amount im willing to lose, if it doesnt work. Lets hope investors and patients will be rewarded. Not investment advice. Do your DD!!
16
Marypennsylvanialand
$ANVS i gotta believe that the only people selling at this level are taking advantage of showing a loss for income tax purposes. I also expect an increase in buying next year, after those losses have already hit the books.
1
11
Dopamineaddict
$ANVS Still beating the open label Ext data release drum. GANX is up about 40% after releasing open label extension data on a phase one consisting of 13 patients, treating for Parkinson’s. ANVS has an open label Ext from a phase 3, with hundreds of patients . It is expected that hundreds of patients have completed six months in the trial. It is expected that a significant portion of these have Parkinson’s dementia, which strongly relates to their current Alzheimer’s trial. In January or February 2027, they should have a cohort from this trial that have completed a year on the open label Ext, similar to GANX.
16
Timustx
$ANVS interesting insider buying. 5 million is no small amount to place a bet on a bio company.
17
Always_neutral
$ANVS Do your DD but only thing I can say is that "DO NOT SELL". Even if you don't believe in this drug, you will get better opportunities down the road before the readout. Folks have started to build their position here. Again, do your own DD.
15
moneyonthebrain
$ANVS $AVXL I remember a time when the crossing of the share prices of these two was a noteworthy matter in the rivalry... it's a bit embarrassing at these levels...
14
stiilthz
$ANVS Canaccord Genuity analyst reiterated a Buy rating on Annovis Bio today and set a price target of $17.00.
14
Dopamineaddict
$ANVS Neurofilament light chain (NfL) acts as the key downstream barometer of axonal damage, scaling from a 2% to 3% normal annual increase up to 5% to 8% per year in mild impairment, and reaching 15% to 20%+ per year in moderate Alzheimer's. As clinical data shows, NfL tracks directly with disease progression and clinical benefit. While monoclonal antibodies like Leqembi and Kisunla (alongside ASO diranersen) primarily show attenuation or stabilization of this upward NfL drift—and in some cases like donanemab fail to decouple plasma NfL from placebo over 76 weeks—buntanetap stands apart. In its Phase 2/3 trial, buntanetap demonstrated actual downward movement and absolute lowering of NfL, total tau, and neuroinflammatory markers from baseline within just 12 weeks. If only we had a biomarker that directly measures neuronal damage and tracks actual disease progression with high accuracy... oh wait, we do. Yet somehow, it remains an afterthought for most Alzheimer's investors.
13
Biotechgod8797
$ANVS to be fair to the company, the Chairman did buy 5 million shares, which isn’t a small amount, in fact its a very sizeable amount by any stock market standards. you never know, look at cidara. went up 70x and then bought by Merck.
14
LeftyT
$ANVS The bandaid has been ripped off and the fear of funding thesis has been put to rest. They now have enough cash to get through the March readout on their key AD trial. I doubled my position at 80 cents and added a bunch of cheap April calls. Shares are still trading at a 10% discount to what the big boys, and the Chairman of the Board just paid. GLTA longs!!! AD patients around the world really, really need this to succeed.
14
808lion
$ANVS For large institutions and big pharma they see the potential for Buntanetap to capture at least $2B/year in annual sales at a minimum. Based on current wall street sales to valuation ratio for pharma which is around approximately 2 to 3 times annual sales, which will put ANVS around $4B to $6B in valuation, and this does not include PD. People will disagree with this analysis from retail perspective that the company is failed not meeting the primary end points, but for large institutions and big pharma they have a different perspective based on the what is currently available on the market that is Leqembi & Kisunla.
8

Advertisement|Remove ads.